외용약 수탁 제조 시장 규모, 점유율, 동향 분석 보고서 : 제품 유형별, 사업 규모별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Topical Drugs Contract Manufacturing Market Growth & Trends:

The global topical drugs contract manufacturing market is expected to reach USD 54.55 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 11.05% from 2025 to 2030. Currently, the global market for contract manufacturing of topical drugs is currently experiencing significant growth, driven by evolving therapeutic needs, outsourcing trends, and advancements in technology. Moreover, with the increasing prevalence of dermatological conditions, coupled with a rising geriatric population and a preference for non-invasive drug delivery methods such as creams, gels, ointments, sprays, and transdermal patches has made outsourcing services like Contract Manufacturing Organizations (CMOs) essential for optimizing costs, ensuring regulatory compliance, and enhancing production capabilities. In addition, CMOs offer numerous advantages that support streamline operations, lower in-house manufacturing expenses, and speed up product commercialization, further contributing to market expansion. In addition, with the rising consumer demand for topical drugs, outsourcing has become a strategic priority, particularly for semi-solid and transdermal product lines that require specialized expertise and adaptable infrastructure.

Furthermore, cost dynamics play a crucial role in the growth of the market. Based on the pricing analysis, the North America provides high-quality manufacturing that complies with regulatory standards, while the Asia Pacific's countries like India, China, and South Korea offers more cost-effective production options with growing capabilities. Factors such as lower labor costs, supportive government policies, and a developing infrastructure complaint with Good Manufacturing Practices (GMP) are fueling the market in Asia Pacific. Furthermore, technological innovations such as continuous manufacturing, nanoencapsulation, advanced homogenization, and 3D printing are improving formulation accuracy, bioavailability, and batch consistency. These advancements support the CMOs to meet complex product demands and meet rising consumer expectations for efficacy and customization.

Furthermore, pricing models are evolving with aligning financial results with performance. However, external factors like U.S. tariffs on imported active pharmaceutical ingredients (APIs) and excipients have created cost pressures in the supply chain, particularly impacting exporters. Despite these challenges, the market is expected to witness growth during the forecast period. Likewise, strategic initiatives and accelerating product launches drive the market. For instance, in July 2024, Arcutis Biotherapeutics, Inc. announced the release of ZORYVE cream 0.15% for the treatment of mild to moderate atopic dermatitis in both adults and children under 6 in the U.S. This new cream, which is applied once daily and contains no steroids, provides quick relief from symptoms and reduces itching, allowing for better long-term management of the condition. Such innovations are expected to further propel the market during the forecast period.

Topical Drugs Contract Manufacturing Market Report Highlights:

• The semi-solid formulations segment dominated the market, with a share of 65.54% in 2024. This growth is driven by the increasing prevalence of skin diseases, patient preferences for targeted therapies, the convenience of semi-solid formulations, and the demand for improved drug absorption, stability, and aesthetic appeal within both therapeutic and cosmetic sectors.
• Based on the scale of operation, the commercial segment held the largest market share in 2024, attributed to the growing trend toward outsourcing, increased demand for dermatological and transdermal therapies, regulatory compliance, increased cost efficiency, and the rising complexity of formulations that require specialized manufacturing expertise.
• The pharmaceutical companies segment held the largest market share in 2024 based on end-use. These companies leverage CMO services due to increasing demand for non-invasive therapies, treatments for chronic skin conditions, improved patient compliance, and opportunities within cosmetic dermatology and advanced transdermal drug delivery systems.
• North America is expected to register a growth rate of 10.37% CAGR over the forecast period due to the rising number of contract manufacturing organizations(CMOs) in countries such as the U.S. and Canada. In addition, the availability of a skilled workforce and regulatory scenarios are expected to significantly contribute to the market's expansion in this region.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Product Type
  • 1.2.2. Scale of Operation
  • 1.2.3. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Topical Drugs Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Pricing Model Analysis
• 3.4. Technology Landscape
• 3.5. Market Analysis Tools
  • 3.5.1. Porter's Five Force Analysis
  • 3.5.2. PESTEL by SWOT Analysis
  • 3.5.3. COVID-19 Impact Analysis

Chapter 4. Topical Drugs Contract Manufacturing Market: Product Type Estimates & Trend Analysis

• 4.1. Topical Drugs Contract Manufacturing Market, By Product Type: Segment Dashboard
• 4.2. Topical Drugs Contract Manufacturing Market, By Product Type: Movement Analysis
• 4.3. Topical Drugs Contract Manufacturing Market Estimates & Forecasts, By Product Type, 2018 - 2030
• 4.4. Semi-Solid Formulations
  • 4.4.1. Semi-Solid Formulations Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Creams
    • 4.4.2.1. Creams Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Ointments
    • 4.4.3.1. Ointments Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.4. Gel
    • 4.4.4.1. Gel Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.5. Others
    • 4.4.5.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Liquid Formulations
  • 4.5.1. Liquid Formulations Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Solid Formulations
  • 4.6.1. Solid Formulations Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Transdermal Products
  • 4.7.1. Transdermal Products Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Topical Drugs Contract Manufacturing Market: Scale of Operation Estimates & Trend Analysis

• 5.1. Topical Drugs Contract Manufacturing Market, By Scale of Operation: Segment Dashboard
• 5.2. Topical Drugs Contract Manufacturing Market, By Scale of Operation: Movement Analysis
• 5.3. Topical Drugs Contract Manufacturing Market Estimates & Forecasts, By Scale of Operation, 2018 - 2030
• 5.4. Clinical
  • 5.4.1. Clinical Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Commercial
  • 5.5.1. Commercial Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Topical Drugs Contract Manufacturing Market: End Use Estimates & Trend Analysis

• 6.1. Topical Drugs Contract Manufacturing Market, By End Use: Segment Dashboard
• 6.2. Topical Drugs Contract Manufacturing Market, By End Use: Movement Analysis
• 6.3. Topical Drugs Contract Manufacturing Market Estimates & Forecasts, By End Use, 2018 - 2030
• 6.4. Pharmaceutical Companies
  • 6.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Biopharmaceutical Companies
  • 6.5.1. Biopharmaceutical Companies Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Others
  • 6.6.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Topical Drugs Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2024 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. North America
  • 7.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.2. U.S
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Competitive Scenario
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.7. Sweden
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.8. Denmark
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.5. Thailand
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6.7. Australia
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Company Market Share/Assessment Analysis, 2024
• 8.3. Company Profiles
  • 8.3.1. MedPharm
    • 8.3.1.1. Company Overview
    • 8.3.1.2. Financial Performance
    • 8.3.1.3. Service Benchmarking
    • 8.3.1.4. Strategic Initiatives
  • 8.3.2. DPT Laboratories Ltd
    • 8.3.2.1. Company Overview
    • 8.3.2.2. Financial Performance
    • 8.3.2.3. Service Benchmarking
    • 8.3.2.4. Strategic Initiatives
  • 8.3.3. Cambrex Corporation
    • 8.3.3.1. Company Overview
    • 8.3.3.2. Financial Performance
    • 8.3.3.3. Service Benchmarking
    • 8.3.3.4. Strategic Initiatives
  • 8.3.4. Kindeva Drug Delivery
    • 8.3.4.1. Company Overview
    • 8.3.4.2. Financial Performance
    • 8.3.4.3. Service Benchmarking
    • 8.3.4.4. Strategic Initiatives
  • 8.3.5. AbbVie Contract Manufacturing
    • 8.3.5.1. Company Overview
    • 8.3.5.2. Financial Performance
    • 8.3.5.3. Service Benchmarking
    • 8.3.5.4. Strategic Initiatives
  • 8.3.6. NextPharma
    • 8.3.6.1. Company Overview
    • 8.3.6.2. Financial Performance
    • 8.3.6.3. Service Benchmarking
    • 8.3.6.4. Strategic Initiatives
  • 8.3.7. Catalent Pharma Solutions
    • 8.3.7.1. Company Overview
    • 8.3.7.2. Financial Performance
    • 8.3.7.3. Service Benchmarking
    • 8.3.7.4. Strategic Initiatives
  • 8.3.8. Thermo Fisher Scientific
    • 8.3.8.1. Company Overview
    • 8.3.8.2. Financial Performance
    • 8.3.8.3. Service Benchmarking
    • 8.3.8.4. Strategic Initiatives
  • 8.3.9. Lonza Group
    • 8.3.9.1. Company Overview
    • 8.3.9.2. Financial Performance
    • 8.3.9.3. Service Benchmarking
    • 8.3.9.4. Strategic Initiatives
  • 8.3.10. The Lubrizol Corporation
    • 8.3.10.1. Company Overview
    • 8.3.10.2. Financial Performance
    • 8.3.10.3. Service Benchmarking
    • 8.3.10.4. Strategic Initiatives
  • 8.3.11. SGS S.A.
    • 8.3.11.1. Company Overview
    • 8.3.11.2. Financial Performance
    • 8.3.11.3. Service Benchmarking
    • 8.3.11.4. Strategic Initiatives
  • 8.3.12. Bora Pharmaceutical CDMO
    • 8.3.12.1. Company Overview
    • 8.3.12.2. Financial Performance
    • 8.3.12.3. Service Benchmarking
    • 8.3.12.4. Strategic Initiatives